Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sepracor, Inc. |
---|---|
Information provided by: | Sepracor, Inc. |
ClinicalTrials.gov Identifier: | NCT00435279 |
To evaluate the antidepressant effect of adjunctive treatment with Eszopiclone in subjects receiving venlafaxine for the treatment of Major Depressive Disorder (MDD).
Condition | Intervention | Phase |
---|---|---|
Major Depressive Disorder Insomnia |
Drug: Eszopiclone Drug: Placebo Drug: Venlafaxine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-Administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-Existing Insomnia |
Estimated Enrollment: | 640 |
Study Start Date: | June 2007 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Eszopiclone: Experimental |
Drug: Eszopiclone
Eszopiclone 3 mg
Drug: Venlafaxine
Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
|
Placebo: Experimental |
Drug: Placebo
Placebo
Drug: Venlafaxine
Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
|
This is a double-blind, randomized, placebo-controlled, parallel-group study. The study consists of two groups of subjects with Major Depressive Disorder randomized to treatment with either eszopiclone 3 mg or placebo nightly at bedtime for 31 weeks beginning the night of Visit 2. In addition, all subjects will receive open-label treatment with venlafaxine. Safety and efficacy will be evaluated using clinical observations as well as physician and subject administered ratings scales.
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Chair: | Medical Director, CNS | Sepracor, Inc. |
Responsible Party: | Sepracor Inc. ( Judith Dunn, Ph.D. ) |
Study ID Numbers: | 190-062 |
Study First Received: | February 12, 2007 |
Last Updated: | December 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00435279 |
Health Authority: | United States: Food and Drug Administration |
Insomnia Depression Major Depressive Disorder |
Sleep Initiation and Maintenance Disorders Depression Mental Disorders Venlafaxine Mood Disorders Dyssomnias |
Sleep Disorders Depressive Disorder, Major Depressive Disorder Serotonin Sleep Disorders, Intrinsic Behavioral Symptoms |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Psychotropic Drugs Serotonin Uptake Inhibitors |
Pharmacologic Actions Pathologic Processes Serotonin Agents Therapeutic Uses Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |